Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis’ Tasigna shows leukaemia therapy benefits beyond end of treatment

Novartis’ Tasigna shows leukaemia therapy benefits beyond end of treatment

6th June 2016

Novartis has announced new clinical trial data that demonstrates the treatment-free remission benefits associated with its cancer drug Tasigna.

The company has reported results from the ENESTfreedom and ENESTop trials at the annual meeting of the American Society of Clinical Oncology, showing that chronic myeloid leukaemia patients can continue to benefit from Tasgina even after they stop taking it.

These studies were designed to evaluate the drug's potential to maintain molecular response after stopping therapy in adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia who had achieved a sustained deep level of molecular response.

It was shown that more than 50 percent of patients who met the predefined response criteria were able to maintain molecular response after stopping Tasigna, both in the first-line setting and after switching from Glivec.

Discussions with regulatory authorities are now underway based on this data, with potential submissions planned for 2016.

Dr Alessandro Riva, global head of Novartis' oncology development and medical affairs, said: "The exploration of TFR in patients treated with Tasigna, which includes Novartis support of eight TFR studies, is the next step in our commitment to advancing care for patients living with this disease."ADNFCR-8000103-ID-801819750-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.